NSAID’s and Drug Profile - Couverture souple

Vishwakarma, Pushpendra Kumar

 
9783845415437: NSAID’s and Drug Profile
Couverture souple
ISBN 10 : 3845415436 ISBN 13 : 9783845415437
Editeur : LAP LAMBERT Academic Publishing, 2011

Synopsis

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of organic acids that have analgesic, anti-inflammatory, and antipyretic properties. NSAIDs are inhibitors of the enzyme cyclo-oxygenase, and so directly inhibit the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. There are 2 forms of cyclo-oxygenase (COX), COX-1, which is the constitutive form of the enzyme, and COX-2, which is the form induced in the presence of inflammation. Inhibition of COX-2 is therefore thought to be responsible for at least some of the analgesic, anti-inflammatory, and antipyretic properties of NSAIDs whereas inhibition of COX-1 is thought to produce some of their toxic effects, particularly those on the gastrointestinal tract. Most of the NSAIDs currently available for clinical use inhibit both COX-1 and COX-2, although selective COX-2 inhibitors such as celecoxib are now available.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Présentation de l'éditeur

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of organic acids that have analgesic, anti-inflammatory, and antipyretic properties. NSAIDs are inhibitors of the enzyme cyclo-oxygenase, and so directly inhibit the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. There are 2 forms of cyclo-oxygenase (COX), COX-1, which is the constitutive form of the enzyme, and COX-2, which is the form induced in the presence of inflammation. Inhibition of COX-2 is therefore thought to be responsible for at least some of the analgesic, anti-inflammatory, and antipyretic properties of NSAIDs whereas inhibition of COX-1 is thought to produce some of their toxic effects, particularly those on the gastrointestinal tract. Most of the NSAIDs currently available for clinical use inhibit both COX-1 and COX-2, although selective COX-2 inhibitors such as celecoxib are now available.

Biographie de l'auteur

Pushpendra Kumar Vishwakarma have done B.Pharma from oriental college of pharmacy Bhopal, MP ,INDIA .He has been selected as Top 100 Educators of 2011 by Cambridge, UK.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Éditeur
LAP LAMBERT Academic Publishing
Date d'édition
2011
Langue
anglais
ISBN 10 
3845415436
ISBN 13 
9783845415437
Reliure
Broché
Nombre de pages
136
Coordonnées du fabricant
non disponible
Personne responsable
KreGa Onlinehandel GmbH
4950000000000
info@krega-onlinehandel.de

Birkenweg 31
Brakel
33034
Allemagne